Incyte Corp (NASDAQ:INCY)
| 54.96 Delayed Data As of 3:59pm ET |  +0.94 / +1.74%Today’s Change | 50.27 Today|||52-Week Range 86.29 | -31.57% Year-to-Date |
Latest INCY News | Press Releases
| Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue? Dec 01 / Zacks.com - Paid Partner Content | Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug Nov 23 / Zacks.com - Paid Partner Content |
| Why Is Incyte (INCY) Down 1.8% Since Last Earnings Report? Nov 30 / Zacks.com - Paid Partner Content | MorphoSys (MOR) Down 22% on Mixed Data From Myelofibrosis Study Nov 22 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 54.02 |
| Today’s open | 55.04 |
| Day’s range | 54.70 - 55.93 |
| Volume | 99,837 |
| Average volume (3 months) | 1,690,068 |
| Market cap | $12.1B |
Data as of 3:59pm ET, 12/04/2023
Growth & Valuation
| Earnings growth (last year) | -64.34% |
| Earnings growth (this year) | +76.11% |
| Earnings growth (next 5 years) | +31.00% |
| Revenue growth (last year) | +13.67% |
| P/E ratio | 29.2 |
| Price/Sales | 5.30 |
| Price/Book | 2.75 |
Financials
| Next reporting date | February 15, 2024 |
| EPS forecast (this quarter) | $0.93 |
| Annual revenue (last year) | $3.4B |
| Annual profit (last year) | $340.7M |
| Net profit margin | 10.04% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Wilmington, Delaware |
Forecasts
